Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme-Reference-Cited by-同舟云学术

Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme

Published:2016-02 Issue:1 Volume:14 Page:48-55
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Maines Francesca,Caffo Orazio,De Giorgi Ugo,Fratino Lucia,Lo Re Giovanni,Zagonel Vittorina,D'Angelo Alessandro,Donini Maddalena,Verderame Francesco,Ratta Raffaele^ORCID,Procopio Giuseppe,Campadelli Enrico,Massari Francesco,Gasparro Donatello,Ermacora Paola,Messina Caterina,Giordano Monica,Alesini Daniele,Basso Umberto,Fraccon Anna Paola^ORCID,Vicario Giovanni,Conteduca Vincenza,Galligioni Enzo

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference20 articles.

1. Cancer statistics, 2014;Siegel;CA Cancer J Clin,2014

2. Treatment of prostate cancer in unfit senior adult patients;Falci;Cancer Treat Rev,2009

3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

4. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

5. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate Cancer in Older Adults with Frailty;Frailty in Older Adults with Cancer;2022

2. Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score–weighted comparative cohort study;European Journal of Cancer;2021-07

3. Real world treatment utilization patterns in patients with castration-resistant prostate cancer;Scandinavian Journal of Urology;2021-06-07

4. Evaluation of dried blood spots as an alternative matrix for therapeutic drug monitoring of abiraterone and delta(4)-abiraterone in prostate cancer patients;Journal of Pharmaceutical and Biomedical Analysis;2021-02

5. Enzalutamide versus Abiraterone Acetate as ﬁrst-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients;Journal of Men’s Health;2021